Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-mutant Non-Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02191891
What this trial is testing

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 32
Testing effectiveness (Phase 2)Looking for participantsNCT07774520
What this trial is testing

Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy

Who this might be right for
Non-small Cell Lung Cancer(NSCLC)EGFR Mutant
Samsung Medical Center 1,173
Testing effectiveness (Phase 2)Active Not RecruitingNCT03586453
What this trial is testing

Osimertinib In EGFR Mutant Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Dana-Farber Cancer Institute 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03392246
What this trial is testing

Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Dana-Farber Cancer Institute 25
Testing effectiveness (Phase 2)UnknownNCT03904823
What this trial is testing

Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

Who this might be right for
EGFR-mutant Non-Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 58
Large-scale testing (Phase 3)Not Yet RecruitingNCT07680790
What this trial is testing

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 850
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07413952
What this trial is testing

Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases

Who this might be right for
NSCLC
The First Affiliated Hospital of Guangzhou Medical University 45
Testing effectiveness (Phase 2)UnknownNCT05534113
What this trial is testing

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Who this might be right for
Non-small Cell Lung Cancer
The First Affiliated Hospital with Nanjing Medical University 38
Large-scale testing (Phase 3)Ended earlyNCT02322281
What this trial is testing

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 149
Not applicableUnknownNCT05377788
What this trial is testing

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaEGFR T790M
Samsung Medical Center 900
Large-scale testing (Phase 3)Study completedNCT01724801
What this trial is testing

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer

Who this might be right for
Brain MetastasisNon Small Cell Lung Cancer
Guangdong Association of Clinical Trials 176
Large-scale testing (Phase 3)UnknownNCT04500704
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 166
Early research (Phase 1)Study completedNCT02503774
What this trial is testing

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Who this might be right for
Solid Tumors
MedImmune LLC 192
Large-scale testing (Phase 3)UnknownNCT04874844
What this trial is testing

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

Who this might be right for
NSCLC
Beijing Dongfang Biotech Co., Ltd. 420
Early research (Phase 1)UnknownNCT05489731
What this trial is testing

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer

Who this might be right for
Advanced Non-small Cell Lung Cancer
Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. 72
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07001995
What this trial is testing

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

Who this might be right for
Small Cell Lung CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer NSCLC
Hunan Province Tumor Hospital 30
Not applicableStudy completedNCT06613633
What this trial is testing

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Who this might be right for
Third-generation TKINSCLC (Advanced Non-small Cell Lung Cancer)
Fudan University 4,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT03433469
What this trial is testing

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Who this might be right for
Stage I Non-Small Cell Lung CancerStage IA Non-Small Cell Lung CancerStage IB Non-Small Cell Lung Cancer+4 more
University of California, San Francisco 27
Testing effectiveness (Phase 2)Looking for participantsNCT05334277
What this trial is testing

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 280
Early research (Phase 1)Looking for participantsNCT07462377
What this trial is testing

EPI-326 in EGFR-mutant NSCLC and HNSCC

Who this might be right for
Epidermal Growth FactorEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Gene Mutation+12 more
EpiBiologics 110
Next Page